Back to Search Start Over

Effect of montelukast on clinical score and cytokine levels of infants for clinically diagnosed acute bronchiolitis.

Authors :
Tahan F
Celik S
Eke Gungor H
Source :
Allergologia et immunopathologia [Allergol Immunopathol (Madr)] 2015 Jul-Aug; Vol. 43 (4), pp. 376-82. Date of Electronic Publication: 2015 Jan 07.
Publication Year :
2015

Abstract

Background: Acute bronchiolitis comprises a major cause for morbidity in infants with viral infection which induces an immune inflammatory response that may produce long lasting harmful effects. Currently, there is no effective therapy for bronchiolitis.<br />Objective: Our aim was to investigate the efficacy of five-day montelukast therapy in acute bronchiolitis management.<br />Methods: The study included 50 infants with acute bronchiolitis. The infants with first episode of acute bronchiolitis were randomly assigned to receive daily montelukast dose of 4mg over five days after admission or no treatment. Plasma eotaxin, IL-4, IL-8 and IFN-gamma levels were evaluated before and after treatment by ELISA method. In the present study, the primary outcome measure was change in clinical severity score, whilst secondary outcome measures were changes in plasma eotaxin, IL-4, IL-8, IFN-gamma levels.<br />Results: No significant differences was found in clinical severity score with five-day montelukast treatment (p>0.05, Mann-Whitney U test). There were no significant differences in plasma eotaxin, IL-4, IL-8, IFN-gamma levels between the groups (p>0.05 Mann-Whitney U test). There was significant decrease in plasma IFN-gamma levels following five-day montelukast treatment (p=0.027, Wilcoxon). There were no significant differences in plasma IL-4, IL-8, IFN-gamma levels between the groups after five-day montelukast treatment (p>0.05, Wilcoxon). There was significant increase in eotaxin levels after five-day montelukast treatment (p=0.009, Wilcoxon).<br />Conclusion: Our study showed that montelukast affected plasma IFN-gamma and eotaxin levels after five days of treatment. Further studies are needed to demonstrate effects of montelukast on chemokine levels in bronchiolitis.<br /> (Copyright © 2014 SEICAP. Published by Elsevier Espana. All rights reserved.)

Details

Language :
English
ISSN :
1578-1267
Volume :
43
Issue :
4
Database :
MEDLINE
Journal :
Allergologia et immunopathologia
Publication Type :
Academic Journal
Accession number :
25575728
Full Text :
https://doi.org/10.1016/j.aller.2014.06.008